Navigation Links
Funding for Orphan Disease Indication Will Compare EpiVax's Tregitope with IVIG
Date:11/16/2012

PROVIDENCE, R.I., Nov. 16, 2012 /PRNewswire/ -- Full Article Here

(Logo:  http://photos.prnewswire.com/prnh/20121116/NE15175LOGO )

Providence-based biotech company EpiVax, Inc. was awarded a new $55,000 grant from the GBS-CIDP Foundation International, to explore using Tregitopes as a novel immuno-modulator therapy for a nerve disease that is currently treated with intravenous immunoglobulin G (IVIG). This award and the recent addition of an SBIR grant for $600,000 to explore the use of Tregitope for Pompe disease (August 2012) will bring the total amount of funding awarded to EpiVax for research and development of Tregitopes to $3.4M in 2012. The surge in funding will result in expansion at the Providence-based biotech company, that is working on spinning off the Tregitope technology into a new venture or angel-backed company.

The GBS-CIDP Foundation research funds will be devoted to developing a safer, more effective replacement for IVIG in the treatment of patients with CIDP (Chronic Inflammatory Demyelinating Polyneuropathy). CIDP patients develop a debilitating nerve condition that requires treatment with IVIG. A single dose of IVIG costs $8,000, and patients often spend tens of thousands of dollars obtaining treatment per year. Alternative treatments that might redirect the immune response toward antigen-specific tolerance without immunosuppressive agents are needed.

The company has been extremely successful in SBIR funding for the Tregitope endeavor despite the constrained funding environment. SBIR grants awarded to EpiVax this year include a Phase I for testing the ability for Tregitopes to reduce inhibitors to FVIII, a separate Phase I SBIR for testing the ability of Tregitopes to reduce immune responses to GAA, a protein that is deficient in Pompe's disease, and a Phase II award to perform safety, toxicity and formulation studies on Tregitopes in the NOD model of Type 1 Diabetes.

About Tregitopes

Tregitopes are linear sequences of peptides contained within the framework of monoclonal antibodies and immunoglobulin-G ,which activate natural regulatory T cells. Tregitopes act as a natural 'off switch' and have been shown in standard preclinical models, and by collaborating laboratories, to suppress and treat autoimmune disease, allergies, and to effectively suppress the immunogenicity of co-administered proteins. This is a natural mechanism for suppressing tissue-destroying immune cells that are the root cause of 'organ-specific autoimmune diseases', in addition, modifying immune responses to biotherapeutics (such as FVIII and other biologics).

Tregitopes were discovered by the team of Anne S. De Groot and Bill Martin at EpiVax.

www.EpiVax.com

CONTACT:  Anthony Marcello, +1-401-272-2123, amarcello@epivax.com


'/>"/>
SOURCE EpiVax, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
2. Research and education success earns more NSF funding
3. Auxogyn Completes $20 Million In Series A Funding
4. NeuroPhage Receives Michael J. Fox Foundation Funding for Parkinsons Disease Research
5. AquaLiv Technologies, Inc. and Its Subsidiary, AquaLiv, Inc., Release Funding Updates
6. Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
7. U.S. Senate Urged to Increase Federal Funding for Research into Hereditary Angioedema, a Rare and Serious Genetic Disorder
8. Glythera Relocates to North East as Part of £2M Funding Round
9. Funding boost for silicon carbide super chip
10. Laboratory Decision Makers Cautiously Optimistic about Funding Conditions, Finds Frost & Sullivan
11. Heartland Plant Innovations Wins Kansas Bioscience Authority Funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... the previously announced identification of its first three targets, it has identified a ... Amyloid beta (Aß), implicated in the development and progression of Alzheimer’s disease (AD). ...
(Date:5/4/2016)... ... May 04, 2016 , ... Proove Biosciences, Inc. , the commercial and ... McGill University . The partnership is designed to advance research in pain genetics ... patients in pain. With the new agreement, researchers at Proove Biosciences are able to ...
(Date:5/4/2016)... York , May 4, 2016 ... Transparency Market Research "Metabolomics Market - Global Industry Analysis, ... the metabolomics market is anticipated to expand at a ... USD 2,494.8 million by 2024. Metabolomics is ... metabolites, within cells, biofluids, tissues or organisms. Together, these ...
(Date:5/3/2016)... May 3, 2016 ... Drug Discovery, Gene Expression) Lab-on-a-chip (IVD & ... Institutes, Diagnostics Centers), Fabrication Technology (Microarrays, Microfluidics) ... the market is expected to reach USD ... Billion in 2015, growing at a CAGR ...
Breaking Biology Technology:
(Date:3/3/2016)... , March 3, 2016  FlexTech, a SEMI ... categories of Innovation, Research & Development, Leadership in Education, ... This is the 9 th year of the ... of companies and individuals from past years . ... on a pre-described set of criteria, by a panel ...
(Date:3/3/2016)... and DE SOTO, Kansas , March ... Detection Plus® to offer Oncimmune,s Early CDT®-Lung, a ... early detection of lung cancer Early CDT®-Lung ... and individuals. --> Early CDT®-Lung test to ... --> Oncimmune, a leader in early cancer ...
(Date:3/2/2016)... 2016 http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) ... "Global Biometrics as a Service Market 2016-2020" ... --> http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has announced the ... a Service Market 2016-2020" report to ... and Markets ( http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has announced ...
Breaking Biology News(10 mins):